Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H20ClN3O |
Molecular Weight | 269.77 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCNC(=O)C1=CC=C(N)C(Cl)=C1
InChI
InChIKey=YEYAKZXEBSVURO-UHFFFAOYSA-N
InChI=1S/C13H20ClN3O/c1-3-17(4-2)8-7-16-13(18)10-5-6-12(15)11(14)9-10/h5-6,9H,3-4,7-8,15H2,1-2H3,(H,16,18)
Molecular Formula | C13H20ClN3O |
Molecular Weight | 269.77 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/9482687Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/10226556 |http://www.prnewswire.com/news-releases/oxigene-initiates-phase-ii-trials-for-declopramide-an-apoptosis-inducing-and-nf-kappa-beta-inhibiting-cancer-drug-candidate-76239792.html | http://adisinsight.springer.com/drugs/800007055
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9482687
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/10226556 |http://www.prnewswire.com/news-releases/oxigene-initiates-phase-ii-trials-for-declopramide-an-apoptosis-inducing-and-nf-kappa-beta-inhibiting-cancer-drug-candidate-76239792.html | http://adisinsight.springer.com/drugs/800007055
Declopramide is an apoptosis inducer. Also, it inhibits NFkappaB activation by inhibition of IkappaBbeta breakdown. In preclinical research, Declopramide demonstrated strong antitumor properties. It had been in phase II clinical trials for the treatment of colorectal cancer. However, this research has been discontinued.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094116 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10194550 |
|||
Target ID: GO:0007249 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10576654 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10331648
Rat: 50 mg/kg 3 times per day
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10331648
Human monocytic cells (THP-1) were exposed to 3-chloroprocainamide (3-CPA) at doses 0.2, 1 and 5 mM just before 5 h stimulation with LPS to induce cytokine production. In this experiment, dose dependent inhibition of TNFalpha was paralleled by an equivalent inhibition of IL-1B, IL-6 and IL-8.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:30:08 GMT 2025
by
admin
on
Mon Mar 31 18:30:08 GMT 2025
|
Record UNII |
916GJF577D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C798
Created by
admin on Mon Mar 31 18:30:08 GMT 2025 , Edited by admin on Mon Mar 31 18:30:08 GMT 2025
|
||
|
NCI_THESAURUS |
C1744
Created by
admin on Mon Mar 31 18:30:08 GMT 2025 , Edited by admin on Mon Mar 31 18:30:08 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
891-60-1
Created by
admin on Mon Mar 31 18:30:08 GMT 2025 , Edited by admin on Mon Mar 31 18:30:08 GMT 2025
|
PRIMARY | |||
|
916GJF577D
Created by
admin on Mon Mar 31 18:30:08 GMT 2025 , Edited by admin on Mon Mar 31 18:30:08 GMT 2025
|
PRIMARY | |||
|
7601
Created by
admin on Mon Mar 31 18:30:08 GMT 2025 , Edited by admin on Mon Mar 31 18:30:08 GMT 2025
|
PRIMARY | |||
|
C1772
Created by
admin on Mon Mar 31 18:30:08 GMT 2025 , Edited by admin on Mon Mar 31 18:30:08 GMT 2025
|
PRIMARY | |||
|
DB06421
Created by
admin on Mon Mar 31 18:30:08 GMT 2025 , Edited by admin on Mon Mar 31 18:30:08 GMT 2025
|
PRIMARY | |||
|
70177
Created by
admin on Mon Mar 31 18:30:08 GMT 2025 , Edited by admin on Mon Mar 31 18:30:08 GMT 2025
|
PRIMARY | |||
|
SUB06935MIG
Created by
admin on Mon Mar 31 18:30:08 GMT 2025 , Edited by admin on Mon Mar 31 18:30:08 GMT 2025
|
PRIMARY | |||
|
100000083473
Created by
admin on Mon Mar 31 18:30:08 GMT 2025 , Edited by admin on Mon Mar 31 18:30:08 GMT 2025
|
PRIMARY | |||
|
CHEMBL1618378
Created by
admin on Mon Mar 31 18:30:08 GMT 2025 , Edited by admin on Mon Mar 31 18:30:08 GMT 2025
|
PRIMARY | |||
|
C072799
Created by
admin on Mon Mar 31 18:30:08 GMT 2025 , Edited by admin on Mon Mar 31 18:30:08 GMT 2025
|
PRIMARY | |||
|
DTXSID20862460
Created by
admin on Mon Mar 31 18:30:08 GMT 2025 , Edited by admin on Mon Mar 31 18:30:08 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|